ACUTE MACULAR NEURORETINOPATHY; This spontaneous report was received from literature:  Acute Macular Neuroretinopathy After Sars-Cov-2 Vaccination. Retinal Cases and Brief Reports. This report concerned a 26 year old female. The objective of this study was to present the rare case of a patient who developed acute macular neuroretinopathy (AMN) after administration of a single-dose adenovector coronavirus vaccine. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient denied having any history of hypertension, trauma, hypovolemia, or epinephrine use. The patient denied any recent history of viral illnesses. The patient had no previous medical or ocular history. The patient was previously treated with influenza vaccine for prophylactic vaccination.  The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported, expiry: unknown) dose, start therapy date were not reported 1 total, administered for prophylactic vaccination. The batch number was not reported and has been requested. Concomitant medications included unspecified oral contraceptives.  On an unspecified date, 2 days after vaccination, the patient developed paracentral scotomas in both eyes. On examination, the patient's best-corrected visual acuity was 20/20 in both eyes. There was no afferent pupillary defect, and intraocular pressure was 18 in the right eye and 15 in the left eye. The Slit-lamp biomicroscopy and ophthalmoscopic examination were unremarkable in both eyes. The fundus autofluorescence showed petaloid faintly hypo autofluorescence lesions in the right eye, whereas the left eye appeared normal. The spectral domain optical coherence tomography revealed focal areas of parafoveal hyperreflective bands in the outer retina in both eyes without retinal thickening. The near-infrared reflectance showed wedge-shaped parafoveal lesions pointing to the fovea that corresponded to these lesions. The imaging findings were consistent with acute macular neuroretinopathy (AMN), and conservative management was recommended. Laboratory data (dates unspecified) included: COVID-19 virus test (NR: not provided) Negative, Fundoscopy (NR: not provided) unremarkable in both eyes, Fundus autofluorescence (NR: not provided) hypo autofluorescence lesions, Imaging procedure (NR: not provided) wedge-shaped parafoveal lesions, Intraocular pressure (NR: not provided) 18 in the right eye, 15 in the left eye, Optical coherence tomography (NR: not provided) hyperreflective bands, Slit-lamp examination (NR: not provided) unremarkable in both eyes, and Visual acuity tests (NR: not provided) 20/20. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of acute macular neuroretinopathy was not reported. The authors concluded that increased reporting of etiologies associated with AMN, such as the SARS-CoV-2 vaccination, and improved imaging modalities may improve our understanding of AMN. Further research is warranted to understand this disease, and this case highlights the development of AMN after a SARS-CoV-2 vaccination in an otherwise healthy female patient. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20220149967-COVID-19 VACCINE AD26.COV2.S-acute macular neuroretinopathy. This event(s) is considered not related. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event(s) than the drug. Specifically: CONMEDS-OTHER SUSPECT DRUGS